Session Abstract – PMWC 2022 Silicon Valley


Precision medicine is among the key contributors in progressing cancer survivorship. However, biomarker testing, which is critical to enabling precision medicine treatments, is below guideline recommendations due to various factors. The session will discuss these barriers, as well as bringing tangible and sustainable solutions to patients with cancer through collaboration.

 Session Chair Profile

Ph.D., Head of Medical Diagnostics, US Medical Affairs Oncology, AstraZeneca

Biography
Dr. Omar Perez has over 17 years designing, deploying, and leading high-visibility oncology initiatives supporting global companion diagnostic developments, strategic partnerships and commercialization opportunities. Before joining AstraZeneca, he oversaw the global CDx developments for the GSK oncology portfolio, leading to diagnostic products for niraparib and dostarlimab. During his time at Pfizer, he led global CDx activities supporting the drug approvals of crizotinib, lorlatinib, dacomitinib talazoparib and inotuzomab. Notably, he led the first FDA approved NGS product for multiple targeted agents and helped establish the Center for Precision Medicine in LATAM to support Pfizer oncology products. Dr. Perez’s background includes roles in biotech and diagnostic companies, including co-founding Nodality, a diagnostic company focused on hematological malignancies. He is an inventor of the multiparametric phospho-proteomic flow technologies and an author of 37 publications and 35 patents.


 Speaker Profile

Vice President, Public Affairs, Guardant Health

Biography
Jenn Higgins is responsible for leading and directing the overall government affairs, patient advocacy, public policy, and corporate communications functions for Guardant Health (NASDAQ: GH). As a veteran of Washington DC, Jenn serves as the company’s point of contact with Congress and the Administration, actively working with key health care stakeholders to help shape public debate around issues that matter to Guardant Health. Jenn has spent the past twenty years using her tenacity and policy knowledge to help corporate executives navigate a constantly changing legislative and regulatory landscape. As a lobbyist, Jenn has represented a wide variety of Fortune 500 health care companies before Congress and the Administration, serving as Partner with two prominent lobbying firms. She also worked as an analyst and Special Assistant at the Centers for Medicare & Medicaid Services, with an emphasis on Medicare policy. Jenn attended Davidson College where she received a B.A. in Medical Economics and Ethics.


 Speaker Profile

Director, Precision Medicine Initiatives, LUNGevity Foundation

Biography
Nikki focuses on accelerating access to precision medicine, especially biomarker testing, for lung cancer patients. Nikki came into patient advocacy from multiple roles at pharmaceutical and diagnostic companies including Genentech, Novartis, and Grifols where she collaborated with patient advocacy groups across different cancer types and other diseases in the US and around the world. This has given her a great vantage point to see the true value of patient advocacy-led multi-stakeholder efforts for jump-starting conversations. She believes that patient advocacy organizations play an essential role in convening different players from government to providers, payers, and industry and leading or contributing to critical work that has long lasting impact on patient care.


 Speaker Profile

Ph.D., President, Health Collaborations

Biography
Dr. Kamala Maddali has extensive experience as a strategy leader for precision medicine at Fortune 100 and 500 companies like Merck and Co, Quintiles, Quest Diagnostics implementing corporate strategic initiatives to foster positive growth of the company in precision medicine. Her vision is to ensure that the patient’s voice is heard, and her goal is to help patients with powerful tools from science and innovation for improving global community health. Dr. Maddali is the author of "Becoming a Kamala" a memoir focused on her unique journey which unveils her various avatars in her pursuit towards becoming a better human, woman, and a rare disease patient. In 2021, Dr. Kamala Maddali has been awarded Pharma Voice 2021 Top 100 Most Inspiring Leaders in the Healthcare Industry. The award is prestigious and honorable recognition to be a part of a select group of leaders, mentors, and visionaries in the Life Sciences who inspire change.


 Speaker Profile

Ph.D., Co-founder and CEO, Strata Oncology

Biography
Dan Rhodes is a scientist and entrepreneur focused on precision medicine in oncology. He co-founded Strata Oncology, a venture-backed precision oncology company committed to acceler-ating the impact of precision medicine for patients with cancer. Previously, Dan was VP of Oncology for Thermo Fisher Scientific (Life Technologies) where he oversaw the development of cancer sequencing products and pharma companion diagnostic partnerships. Prior to that, Dan was co-founder and CEO of Compendia Bioscience, a University of Michigan spin-off formed to commercialize his thesis project, Oncomine, a cancer genome data-mining platform. Dan has co-authored 40+ publications and is a co-inventor on 10 patents, including the discov-ery of gene fusions as a genetic cause of prostate cancer. In 2019, Dan was named Ernst & Young Entrepreneur of the Year for the Midwest region. Dan served on the oversight committee for the Michigan Translational Research and Commercialization (MTRAC) Program and on multi-ple advisory boards.